BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

700 related articles for article (PubMed ID: 36700230)

  • 21. Persistent SARS-CoV-2-specific immune defects in kidney transplant recipients following third mRNA vaccine dose.
    Werbel WA; Karaba AH; Chiang TP; Massie AB; Brown DM; Watson N; Chahoud M; Thompson EA; Johnson AC; Avery RK; Cochran WV; Warren D; Liang T; Fribourg M; Huerta C; Samaha H; Klein SL; Bettinotti MP; Clarke WA; Sitaras I; Rouphael N; Cox AL; Bailey JR; Pekosz A; Tobian AAR; Durand CM; Bridges ND; Larsen CP; Heeger PS; Segev DL;
    Am J Transplant; 2023 Jun; 23(6):744-758. PubMed ID: 36966905
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    Borgogna C; Ferrante D; Rosso G; Guglielmetti G; Lo Cigno I; Raviola S; Caneparo V; Quaglia M; Cantaluppi V; Gariglio M
    J Med Virol; 2024 Jun; 96(6):e29710. PubMed ID: 38804187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vaccination with BNT162b2 and ChAdOx1 nCoV-19 Induces Cross-Reactive Anti-RBD IgG against SARS-CoV-2 Variants including Omicron.
    Gerges D; Kapps S; Hernández-Carralero E; Freire R; Aiad M; Schmidt S; Winnicki W; Reiter T; Pajenda S; Schmidt A; Sunder-Plassmann G; Wagner L
    Viruses; 2022 May; 14(6):. PubMed ID: 35746653
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Humoral and cellular immune response to SARS-CoV-2 mRNA BNT162b2 vaccine in pediatric kidney transplant recipients compared with dialysis patients and healthy children.
    Gulmez R; Ozbey D; Agbas A; Aksu B; Yildiz N; Uckardes D; Saygili S; Yilmaz EK; Yildirim ZY; Tasdemir M; Kiykim A; Cokugras H; Canpolat N; Nayir A; Kocazeybek B; Caliskan S
    Pediatr Nephrol; 2023 Jul; 38(7):2199-2208. PubMed ID: 36459243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.
    Ai J; Zhang H; Zhang Y; Lin K; Zhang Y; Wu J; Wan Y; Huang Y; Song J; Fu Z; Wang H; Guo J; Jiang N; Fan M; Zhou Y; Zhao Y; Zhang Q; Liu Q; Lv J; Li P; Qiu C; Zhang W
    Emerg Microbes Infect; 2022 Dec; 11(1):337-343. PubMed ID: 34935594
    [No Abstract]   [Full Text] [Related]  

  • 26. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies.
    Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P
    Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Broad immunity to SARS-CoV-2 variants of concern mediated by a SARS-CoV-2 receptor-binding domain protein vaccine.
    Deliyannis G; Gherardin NA; Wong CY; Grimley SL; Cooney JP; Redmond SJ; Ellenberg P; Davidson KC; Mordant FL; Smith T; Gillard M; Lopez E; McAuley J; Tan CW; Wang JJ; Zeng W; Littlejohn M; Zhou R; Fuk-Woo Chan J; Chen ZW; Hartwig AE; Bowen R; Mackenzie JM; Vincan E; Torresi J; Kedzierska K; Pouton CW; Gordon TP; Wang LF; Kent SJ; Wheatley AK; Lewin SR; Subbarao K; Chung AW; Pellegrini M; Munro T; Nolan T; Rockman S; Jackson DC; Purcell DFJ; Godfrey DI
    EBioMedicine; 2023 Jun; 92():104574. PubMed ID: 37148585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants.
    Seki Y; Yoshihara Y; Nojima K; Momose H; Fukushi S; Moriyama S; Wagatsuma A; Numata N; Sasaki K; Kuzuoka T; Yato Y; Takahashi Y; Maeda K; Suzuki T; Mizukami T; Hamaguchi I
    Med; 2022 Jun; 3(6):406-421.e4. PubMed ID: 35815933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Invasive Monitoring for Rejection in Kidney Transplant Recipients After SARS-CoV-2 mRNA Vaccination.
    Al Jurdi A; Gassen RB; Borges TJ; Solhjou Z; Hullekes FE; Lape IT; Efe O; Alghamdi A; Patel P; Choi JY; Mohammed MT; Bohan B; Pattanayak V; Rosales I; Cravedi P; Kotton CN; Azzi JR; Riella LV
    Front Immunol; 2022; 13():838985. PubMed ID: 35281011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
    Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
    Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inactivated SARS-CoV-2 booster vaccine enhanced immune responses in patients with chronic liver diseases.
    Liu Y; Lu J; Zhan H; Yuan W; Li X; Kang H; Li H; Chen Y; Cheng L; Sun X; Zheng H; Wang W; Dai E; Li Y
    Virol Sin; 2023 Oct; 38(5):723-734. PubMed ID: 37487943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Humoral Response in Kidney Transplant Recipients and Donors and Healthy Volunteers Following Second Dose of SARS-CoV-2 mRNA Vaccine.
    Sasaki H; Hasegawa K; Harada H; Takamoto D; Takada Y; Hirano T; Tanabe T; Tanaka H; Miura M
    Transplant Proc; 2023 Apr; 55(3):514-520. PubMed ID: 36948961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination.
    Assawakosri S; Kanokudom S; Chansaenroj J; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Sudhinaraset N; Mongkolsapaya J; Wanlapakorn N; Honsawek S; Poovorawan Y
    Int J Infect Dis; 2022 Sep; 122():793-801. PubMed ID: 35863731
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    Assawakosri S; Kanokudom S; Suntronwong N; Auphimai C; Nilyanimit P; Vichaiwattana P; Thongmee T; Duangchinda T; Chantima W; Pakchotanon P; Srimuan D; Thatsanatorn T; Klinfueng S; Yorsaeng R; Sudhinaraset N; Wanlapakorn N; Mongkolsapaya J; Honsawek S; Poovorawan Y
    J Infect Dis; 2022 Oct; 226(8):1372-1381. PubMed ID: 35267040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low switched memory B cells are associated with no humoral response after SARS-CoV-2 vaccine boosters in kidney transplant recipients.
    Seija M; García-Luna J; Rammauro F; Brugnini A; Trías N; Astesiano R; Santiago J; Orihuela N; Zulberti C; Machado D; Recalde C; Yandián F; Guerisoli A; Noboa J; Orihuela S; Curi L; Bugstaller E; Noboa O; Nin M; Bianchi S; Tiscornia A; Lens D
    Front Immunol; 2023; 14():1202630. PubMed ID: 37942335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
    Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
    Front Immunol; 2021; 12():747830. PubMed ID: 34858404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
    Wen GP; Zhu M; Li LR; Li XJ; Ye HM; Zhou YL
    Front Immunol; 2023; 14():1099629. PubMed ID: 36817474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.